Shahram Mori, MD, PhD

Physician

Clinical Cancer Research

Expertise of Shahram Mori, MD, PhD

Biography: Shahram Mori, MD, PhD is a highly experienced physician with board-certification in oncology and hematology. After earning a PhD in molecular biology from New Mexico State University, Dr. Mori went on to receive fellowship training in oncology/hematology from Arizona Cancer Center, University of Arizona in Tucson and bone marrow transplantation from City of Hope National Medical Center in Duarte, California. He specializes in treating a wide array of complex blood disorders using blood and bone-marrow transplantation and cellular therapy.
Education: St. George's University School of Medicine
Residency: University of Texas Medical School at Houston
Fellowship: City of Hope
University of Arizona College of Medicine
Board Certifications: Medical Oncology: American board of Internal Medicine

Publications

Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation

2022, ANNALS OF HEMATOLOGY
Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience

2022, INTERNATIONAL JOURNAL OF HEMATOLOGY
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

2020, HAEMATOLOGICA

More sources loaded
Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment

2019, CURRENT TREATMENT OPTIONS IN ONCOLOGY
Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation

2019, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Increased bone marrow CD56(bright) natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome

2019, BONE MARROW TRANSPLANTATION
Higher Risks of Toxicity and Incomplete Recovery in 13-to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results

2019, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma

2019, CUREUS
Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study

2019, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors

2019, HAEMATOLOGICA

Associated Clinical Trials for Shahram Mori, MD, PhD

NCT06619561

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

This study is currently enrolling.

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida
NCT0645646

A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

This study is currently enrolling.

Associated Conditions: Leukemia

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

Overall, the goal of this research study is to determine if tagraxofusp (Tag) in combination with venetoclax (Ven) and azacitidine (Aza) can safely treat cancer in patients who have not received...
NCT06384261

A multicenter, open label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy.

This study is currently enrolling.

Research Area: Clinical Cancer Research

Research Location: Orlando, Florida

The purpose of this study is to see if the investigational study drug, called cusatuzumab, is safe and effective when given together with other standard of care drugs used to treat Acute Myeloid...

More clinical trials loaded
NCT06456463

A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

This study is not currently enrolling.

Associated Conditions: Leukemia

Research Area: Clinical Cancer Research

Shahram Mori, MD, PhD

Expertise of Shahram Mori, MD, PhD

Associated Clinical Trials for Shahram Mori, MD, PhD

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

A multicenter, open label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy.

A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.